Arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVC/D) is an inherited myocardial disease characterized by fibro-fatty replacement of the right ventricular myocardium, and associated with paroxysmal ventricular arrhythmias and sudden cardiac death (SCD). It is currently the second most common cause of SCD after hypertrophic cardiomyopathy in young people <35 years of age, causing up to 20% of deaths in this patient population. This condition has a male preponderance and is more commonly found in individuals of Italian and Greek descent. To date, there is no single diagnostic test for ARVC/D and the diagnosis is made based on clinical, electrocardiographic, and radiological findings according to the Revised 2010 Task Force Criteria. In this review, we will discuss the mainstay treatment which includes pharmacotherapy, implantable cardioverter-defibrillator insertion for abortion of sudden cardiac death, and in the advanced stages of the disease cardiac transplantation.
| INTRODUCTION
Arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVC/ D) is an uncommon inherited cardiac disease characterized by progressive right ventricular (RV) dysfunction due to fibro-fatty replacement of the myocardium and associated with high risk of ventricular arrhythmias and sudden cardiac death (SCD).
1,2 ARVC/D has a predominantly autosomal dominant inheritance, although recessive forms associated with a cutaneous phenotype, such as Naxos disease and Carvajal syndrome, are also observed. 3, 4 Despite RV abnormalities being the predominant finding, it has been recently appreciated that patients with ARVC/D may also have some degree of left ventricular (LV) involvement 5 and indeed severe LV impairment can sometimes be the initial manifestation of the disorder. 6 An LV-predominant form of ARVC/D has recently been described. 7 Independently of which ventricle is initially or predominantly affected, during the later stages, advanced disease can result in biventricular heart failure, which may closely resemble dilated cardiomyopathy (DCM). LV dysfunction is observed more frequently with greater RV dysfunction, worse functional class, and leads to an increased tendency to cardiovascular adverse events relating to heart failure. 8 The same study showed no clear relationship between LV involvement and an increased rate of arrhythmic events. 8 Clinical manifestations vary with the age of the patient and stage of disease. 9 In this article, we will review the pathophysiology or ARVC/D, the main diagnostic modalities used clinically aiding the diagnosis and patient management.
| PATHOPHYSIOLOGY OF ARVC/D
The pathophysiological mechanisms in ARVC/D involve desmosomal abnormalities that can arise from mutations in cell adhesion proteins or intracellular signaling components. 10 A number of genes have been implicated in the pathogenesis of ARVC/D, 11 as illustrated in Table 1 . Particularly, reduced cardiac desmoglein-2 and desmocollin-2 levels appear to be specifically associated with ARVC/D, independent of the gene mutations found. 12 The desmosome normally maintains cell-to-cell adhesion and confers mechanical strength to tissues (Figures 1 and 2 ). In the extracellular space, desmosomal cadherins (desmocollin and desmoglein) bind strongly to each other. Cadherins span the plasma membrane and attach to linker proteins (plakoglobin, desmoplakin, and plakophilin-2) in the intracellular space. 1 Plakoglobin and desmoplakin are intracellular proteins anchoring desmosomes to desmin intermediate filaments. Moreover, plakoglobin contributes to interlinking adherens junctions with the actin cytoskeleton and participates in cellular signaling to the nucleus and desmosome organization. 13, 14 Defects in linking sites of these proteins can interrupt cell adhesion, especially under conditions of increased mechanical stress or stretch, leading to cell death, progressive loss of myocardium, and fibro-fatty replacement. 15 As such, surviving myocardial fibers within the fibro-fatty tissue from zones of slow conduction provide a medium for re-entry ventricular arrhythmias. [16] [17] [18] [19] The degeneration-inflammation model posits that the resulting cellular damage is found in tissues under high mechanical stress. 1 Indeed, this notion is in keeping with the observations that exercise increases age-related penetrance and risk of arrhythmias in ARVC/D-associated mutation carriers. 20 The potential role of calcium-sensitive pathways in the pro-arrhythmia mechanism of ARVC/ D has been proposed. 21 In a recent meta-analysis, however, the presence of desmosomal gene mutations was not associated with global or regional structural and functional alterations, epsilon wave, or VT of left bundle branch morphology. and sudden mortality events. 26 Intracardiac thrombosis may occur in certain patients with ARVC/D. 27 Atrial arrhythmias are also common in ARVC/D and present at a younger age than in the general population. 28 Atrial arrhythmias are associated with male gender, increasing age, and left atrial dilation and clinically important, and they are associated with inappropriate implantable cardioverter-defibrillator shocks 29 and increased risk of both heart failure and death. 28 In addition to tachy-arrhythmias, brady-arrhythmias are also observed in this condition. Table 2) . 31 In the original 1994 TFC, the clinical diagnosis was based strongly on symptomatic index cases and SCD victims-those with overt and severe phenotypes. Consequently, the 1994 criteria were highly specific, but they lacked sensitivity for early and familial disease. [32] [33] [34] [35] A systematic review and meta-analysis of five retrospective studies compared the diagnostic concordance between the 1994 and 2010 criteria. 
| Electrocardiography
In the ECG, epsilon waves, which are late potentials occurring between the end of the QRS complex and the onset of the T-wave, and T-wave inversion in the right precordial leads of V1 to V3 may be observed. Epsilon waves are specific for ARVC/D although it is only observed in 30% of patients and are best seen in the right precordial leads V1-V3 ( Figure 4 ). Particularly, epsilon waves in lead aVR in patients with arrhythmogenic right ventricular cardiomyopathy are rare electrocardiographic findings with a specificity of 100%. 38 The detection of epsilon waves on 12-lead ECG has been associated with higher episodes of sustained VT, but reassuringly, this did not lead to increased SCD incidence. 39 A case of a child with extensive involvement of both right and left ventricular walls and epsilon waves in all precordial leads has been reported. 40 However, interobserver variability in the assessment of epsilon waves is high. 41 As a result, the assessment of the epsilon waves must be performed cautiously particularly in patients with who would not otherwise meet diagnostic criteria. The sensitivity of epsilon waves on the ECG is low between 25% and 38%, and therefore, a normal ECG does not exclude the diagnosis of ARVC/D. 42, 43 The use of Fontaine bipolar precordial lead electrocardiography (F-ECG) increased the sensitivity to 50%. 43 Electrical abnormalities in ARVC/D are important as these changes precede structural changes. 44 A more specialized electrocardiographic technique, known as signal-averaged electrocardiography (SAECG), can also be utilized. It aims to filter interference, unmask any microvariations, and display late potentials (if any) within the QRS complex by averaging the multiple electrical signals generated by the heart. 45 Late potentials are thought to represent electrical depolarization abnormalities and are defined within the minor depolarization criteria in the 2010 TFC (Table 2 ). The criteria include the following: As long as any of the above is satisfied, the minor criterion in the 2010 TFC is fulfilled. Even though SAECG can be useful, it must be noted that an abnormal SAECG is not specific to ARVC as it can also be seen in other conditions such as myocarditis and scarring in ischemic heart disease.
| Imaging: echocardiography and cardiac magnetic resonance (CMR)
Noninvasive imaging modalities such as echocardiography and CMR can be used to identify structural and functional abnormalities described in the revised TFC. It is also possible to investigate these invasively using RV angiography. Echocardiographic features of o Fractional area change ≤33%
• Regional RV akinesia, dyskinesia, and one of the following at end diastole: o RV ejection fraction ≤40%
• Regional RV akinesia or dyskinesia and one of the following:
o Ratio of RV end-diastolic volume to BSA ≥100 mL/m 2 and <110 mL/m 2 (male) or ≥90 mL/m 2 and <100 mL/m 2 (female)
o RV ejection fraction >40% and ≤45%
RV angiography
• Regional RV akinesia, dyskinesia, or aneurysm • Regional RV akinesia, dyskinesia, or aneurysm LI ET AL. phic VT. 48 Furthermore, cardiovascular magnetic resonance and specifically the cardiac volume, in addition to the degree and location of cardiac involvement, can be used to distinguish between these two disease entities. 49 The combined use of signal and wall motion parameters of cardiovascular magnetic resonance has been proposed to be contemporaneously considered for achieving a better diagnostic accuracy for the diagnosis of ARVC/D. 
| Differential diagnosis
It is important to differentiate ARVC/D from other right ventricular disorders, such as Brugada syndrome, as overlapping features may be found. 55 Moreover, cardiovascular conditions such as peripartum cardiomyopathy 46 or athlete's heart can present with similar clinical and imaging findings. 56 A correct diagnosis is important because unlike ARVC/D, athlete's heart would not justify disqualification from competitive sports. 56 Distinguishing between ARVC/D and athlete's heart remains a diagnostic challenge. High-level endurance training is associated with RV elongation, dilation, and hence enlargement compared to isometric physical activities. 57 As such, an enlarged RV dimension alone is not a reliable diagnostic criterion for ARVC/D in elite athletes. A large proportion of athletes also express echocardiographic morphological findings often evident in documented ARVC/D, including rounded RV apex, and prominent RV trabeculations and moderator band. 58 By contrast, impaired RV systolic function is associated only with ARVC/D and not with athlete's heart. The use of both RV dilation and systolic dysfunction might serve as a useful diagnostic tool to separate between the two.
Despite all the imaging parameters, and new normal specific ranges for athletes, 58 reaching a diagnosis of ARVC/D in an athlete can sometimes remain challenging and a short period of detraining with subsequent assessment usually with cardiac MRI can be helpful in resolving this ambiguity. 59 
| MANAGEMENT
In ARVC/D, the main goal is to avoid the high-risk events of malignant arrhythmias and SCD and slow the progression of heart failure. 2, 60 Competitive sports are discouraged. 2, 61 While patients with ARVC are allowed to perform exercise including sports as part of a healthy lifestyle, they should not exercise to maximal capacity and be vigilant to any symptoms of palpitations. 20 Frequent endurance exercise increases the risk for VT/VF and heart failure. 20 The management of patients with ARVC/D in specific situations such as pregnancy is beyond the scope of this review, but is directed to the following reference. 62 Anti-arrhythmic medications, such as F I G U R E 6 Four-chamber view of a cardiovascular magnetic resonance study in diastole (left panel) and systole (right panel) showing a very dilated RV F I G U R E 7 Short-axis section of an explanted heart at the time of heart transplantation for ARVC/D demonstrates the right ventricular wall to be composed of fat tissue, and there is prominent right ventricular trabeculation. The myocardium of the numerous prominent trabecles appears macroscopically unaffected, which has been confirmed histologically beta-blockers and class-III agents, are advised. 2 Sotalol and amiodarone with or without the need for conventional beta-blockers are potent (effective is used in 3 sentences in a row). 16, 63 Calcium channel blockers may be effective in selected patients. 64 The addition of flecainide in combination with sotalol/metoprolol may be an adequate strategy for the control of ventricular arrhythmias in patients with ARVC/D refractory to single-agent therapy and/or catheter ablation. 65 In general, the most sufficient combinations appear to be sotalol or flecainide and amiodarone/beta-blockers. 64 The American College of Cardiology, the American Heart Association and the European Society and Cardiology recommended ICD implantation for the prevention of SCD events. 66 Risk stratification and indication to ICD implantation in ARVC/D has been proposed by an international task force consensus statement. 67 One study reported that the annual cardiac mortality in patients with ARVC/D who were implanted with an ICD was 0.9%. 68 Finally, VT ablation targeting late potentials abolition seems to be effective in preventing VT recurrence in patients with or without RV structural abnormalities. 69 In the multicenter registry, clinical response (freedom from SCD, VT requiring hospitalization, or heart transplantation) after the last ablation (predominantly endocardial) was 86% at 1 year, 69% at 5 years, and 60% at 10 years. 70 On the other hand, the combined endocardial and epicardial approach resulted in better procedural success and long-term VT-free survival compared with the endocardial approach in ARVC/D patients with recurrent VTs. 71, 72 In fact, the combined endocardial and epicardial VT ablation eliminated all clinical and induced VTs, and the addition of scar dechanneling resulted in noninducibility in all cases. 72 Identification of conducting channels (CCs) inside or between the scars can be achieved via endocardial high-density substrate mapping. 73 However, another single-center study showed that the vast majority of critical VT circuits were epicardial while epicardial ablation of VT appeared to be both safe and effective in achieving arrhythmia control in ARVC/D. 74 A recent meta-analysis showed better outcomes with the combined endocardial and epicardial ablation approach compared with the endocardial approach only. 75 However, a stepwise approach with an endocardial ablation first and additional epicardial ablation only if VT episodes are still inducible has been proposed. 76, 77 Furthermore, an inducibility-guided catheter ablation strategy of VT in patients with ARVC/D has been proposed to prevent unnecessary epicardial ablation procedures. 78 Electrical regression of SAECG after catheter ablation in ARVC/D has been found to be associated with fewer ventricular arrhythmia recurrences. 79 Other treatment options like bilateral cardiac sympathectomy need to be studied further in order to investigate its optimal timing and use in ARVC/D management. such as male gender, heart rate variability, and atrial arrhythmias. 28, [82] [83] [84] Other important factors include electrocardiographic characteristics (atrioventricular block, T-wave inversions), 83, 85 echocardiographic parameters (RV diameter), 86 and genetic factors (PKP2 carriers), 87 GT and SW were supported by the Croucher Foundation of Hong Kong.
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